Globus Medical, Inc. (GMED)
USD 81.78
(-1.97%)
USD 81.78
(-1.97%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.56 Billion USD | 53.34% |
| 2022 | 1.02 Billion USD | 6.76% |
| 2021 | 958.1 Million USD | 21.43% |
| 2020 | 789.04 Million USD | 0.47% |
| 2019 | 785.36 Million USD | 10.15% |
| 2018 | 712.96 Million USD | 12.11% |
| 2017 | 635.97 Million USD | 12.76% |
| 2016 | 563.99 Million USD | 3.53% |
| 2015 | 544.75 Million USD | 14.84% |
| 2014 | 474.37 Million USD | 9.19% |
| 2013 | 434.45 Million USD | 12.56% |
| 2012 | 385.99 Million USD | 16.45% |
| 2011 | 331.47 Million USD | 15.02% |
| 2010 | 288.19 Million USD | 13.31% |
| 2009 | 254.34 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 606.66 Million USD | -1.6% |
| 2024 Q3 | 625.7 Million USD | -0.63% |
| 2024 Q2 | 629.69 Million USD | 3.8% |
| 2023 Q4 | 616.53 Million USD | 60.71% |
| 2023 FY | 1.56 Billion USD | 53.34% |
| 2023 Q1 | 276.68 Million USD | 0.8% |
| 2023 Q2 | 291.61 Million USD | 5.39% |
| 2023 Q3 | 383.63 Million USD | 31.56% |
| 2022 Q2 | 263.64 Million USD | 14.36% |
| 2022 Q4 | 274.49 Million USD | 8.01% |
| 2022 Q3 | 254.14 Million USD | -3.6% |
| 2022 FY | 1.02 Billion USD | 6.76% |
| 2022 Q1 | 230.54 Million USD | -7.79% |
| 2021 Q2 | 251.01 Million USD | 10.41% |
| 2021 Q4 | 250.02 Million USD | 8.84% |
| 2021 FY | 958.1 Million USD | 21.43% |
| 2021 Q1 | 227.34 Million USD | -2.61% |
| 2021 Q3 | 229.72 Million USD | -8.48% |
| 2020 Q1 | 190.57 Million USD | -9.96% |
| 2020 FY | 789.04 Million USD | 0.47% |
| 2020 Q4 | 233.44 Million USD | 8.03% |
| 2020 Q3 | 216.09 Million USD | 45.11% |
| 2020 Q2 | 148.92 Million USD | -21.86% |
| 2019 Q3 | 196.21 Million USD | 0.86% |
| 2019 FY | 785.36 Million USD | 10.15% |
| 2019 Q1 | 182.94 Million USD | -6.63% |
| 2019 Q2 | 194.53 Million USD | 6.34% |
| 2019 Q4 | 211.66 Million USD | 7.88% |
| 2018 FY | 712.96 Million USD | 12.11% |
| 2018 Q4 | 195.93 Million USD | 15.78% |
| 2018 Q2 | 173.38 Million USD | -0.59% |
| 2018 Q1 | 174.41 Million USD | -0.92% |
| 2018 Q3 | 169.23 Million USD | -2.39% |
| 2017 Q1 | 155.8 Million USD | 2.78% |
| 2017 Q2 | 152.39 Million USD | -2.19% |
| 2017 Q3 | 151.74 Million USD | -0.42% |
| 2017 FY | 635.97 Million USD | 12.76% |
| 2017 Q4 | 176.03 Million USD | 16.01% |
| 2016 Q1 | 139.26 Million USD | -2.33% |
| 2016 Q3 | 135.65 Million USD | -1.34% |
| 2016 Q2 | 137.48 Million USD | -1.27% |
| 2016 Q4 | 151.59 Million USD | 11.75% |
| 2016 FY | 563.99 Million USD | 3.53% |
| 2015 Q1 | 131.6 Million USD | 2.18% |
| 2015 Q2 | 133.57 Million USD | 1.49% |
| 2015 Q3 | 136.99 Million USD | 2.56% |
| 2015 Q4 | 142.58 Million USD | 4.08% |
| 2015 FY | 544.75 Million USD | 14.84% |
| 2014 Q2 | 113.57 Million USD | -0.56% |
| 2014 Q4 | 128.8 Million USD | 9.35% |
| 2014 Q3 | 117.78 Million USD | 3.71% |
| 2014 Q1 | 114.21 Million USD | -0.9% |
| 2014 FY | 474.37 Million USD | 9.19% |
| 2013 FY | 434.45 Million USD | 12.56% |
| 2013 Q3 | 107.18 Million USD | 0.17% |
| 2013 Q4 | 115.24 Million USD | 7.52% |
| 2013 Q1 | 105.01 Million USD | 4.46% |
| 2013 Q2 | 107 Million USD | 1.9% |
| 2012 Q1 | 94.71 Million USD | 7.64% |
| 2012 FY | 385.99 Million USD | 16.45% |
| 2012 Q4 | 100.53 Million USD | 6.09% |
| 2012 Q3 | 94.76 Million USD | -1.26% |
| 2012 Q2 | 95.97 Million USD | 1.33% |
| 2011 Q4 | 87.99 Million USD | 4.42% |
| 2011 Q2 | 80.93 Million USD | 3.39% |
| 2011 FY | 331.47 Million USD | 15.02% |
| 2011 Q1 | 78.27 Million USD | 0.0% |
| 2011 Q3 | 84.27 Million USD | 4.12% |
| 2010 FY | 288.19 Million USD | 13.31% |
| 2009 FY | 254.34 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott Laboratories | 40.1 Billion USD | 96.089% |
| Allurion Technologies Inc. | 53.46 Million USD | -2833.54% |
| Artivion, Inc. | 354 Million USD | -343.067% |
| Avanos Medical, Inc. | 673.3 Million USD | -132.954% |
| Butterfly Network, Inc. | 65.9 Million USD | -2280.085% |
| Butterfly Network, Inc. | 65.9 Million USD | -2280.085% |
| Bio-Rad Laboratories, Inc. | 2.67 Billion USD | 41.283% |
| Boston Scientific Corporation | 14.24 Billion USD | 88.985% |
| Perspective Therapeutics, Inc. | 7.1 Million USD | -21978.773% |
| CONMED Corporation | 1.24 Billion USD | -26.393% |
| Edwards Lifesciences Corporation | 6 Billion USD | 73.88% |
| Paragon 28, Inc. | 216.38 Million USD | -624.841% |
| Glaukos Corporation | 314.71 Million USD | -398.386% |
| Inspire Medical Systems, Inc. | 624.79 Million USD | -151.037% |
| Integer Holdings Corporation | 1.59 Billion USD | 1.766% |
| Medtronic plc | 32.36 Billion USD | 95.154% |
| Nevro Corp. | 425.17 Million USD | -268.902% |
| Owlet, Inc. | 54.01 Million USD | -2804.047% |
| Penumbra, Inc. | 1.05 Billion USD | -48.176% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 5.54 Billion USD | 71.734% |
| Sonendo, Inc. | 43.86 Million USD | -3475.689% |
| STERIS plc | 5.13 Billion USD | 69.477% |
| Stryker Corporation | 20.49 Billion USD | 92.348% |
| Vapotherm, Inc. | 68.66 Million USD | -2184.111% |
| Zimmer Biomet Holdings, Inc. | 7.39 Billion USD | 78.788% |